
Vincent F Segers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1339182/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Stem-cell therapy for cardiac disease. Nature, 2008, 451, 937-942.	13.7	1,085
2	Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nature Medicine, 2007, 13, 970-974.	15.2	720
3	Local Delivery of Protease-Resistant Stromal Cell Derived Factor-1 for Stem Cell Recruitment After Myocardial Infarction. Circulation, 2007, 116, 1683-1692.	1.6	344
4	Cardiac Progenitor Cells and Biotinylated Insulin-Like Growth Factor-1 Nanofibers Improve Endogenous and Exogenous Myocardial Regeneration After Infarction. Circulation, 2009, 120, 876-887.	1.6	209
5	The continuous heart failure spectrum: moving beyond an ejection fraction classification. European Heart Journal, 2019, 40, 2155-2163.	1.0	195
6	Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 290, H1370-H1377.	1.5	183
7	Biomaterials to Enhance Stem Cell Function in the Heart. Circulation Research, 2011, 109, 910-922.	2.0	161
8	Role of Neuregulin-1/ErbB2 Signaling in Endothelium-Cardiomyocyte Cross-talk. Journal of Biological Chemistry, 2006, 281, 19469-19477.	1.6	154
9	Cardiac endothelium–myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction. European Heart Journal, 2015, 36, 2050-2060.	1.0	126
10	Cardiac Remodeling: Endothelial Cells Have More to Say Than Just NO. Frontiers in Physiology, 2018, 9, 382.	1.3	121
11	Protein Therapeutics for Cardiac Regeneration after Myocardial Infarction. Journal of Cardiovascular Translational Research, 2010, 3, 469-477.	1.1	108
12	Local delivery of proteins and the use of self-assembling peptides. Drug Discovery Today, 2007, 12, 561-568.	3.2	94
13	Heart Failure With Preserved Ejection Fraction: A Review of Cardiac and Noncardiac Pathophysiology. Frontiers in Physiology, 2019, 10, 638.	1.3	87
14	Cellular senescence links aging and diabetes in cardiovascular disease. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 315, H448-H462.	1.5	71
15	Stromal Cell-Derived Factor-1 Retention and Cardioprotection for Ischemic Myocardium. Circulation: Heart Failure, 2011, 4, 509-518.	1.6	69
16	ErbB2 signaling at the crossing between heart failure and cancer. Basic Research in Cardiology, 2016, 111, 60.	2.5	68
17	The role of ErbB4 in cancer. Cellular Oncology (Dordrecht), 2020, 43, 335-352.	2.1	66
18	Inhibitory actions of the NRG-1/ErbB4 pathway in macrophages during tissue fibrosis in the heart, skin, and lung. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 313, H934-H945.	1.5	63

VINCENT F SEGERS

#	Article	IF	CITATIONS
19	Selfâ€assembling peptide nanofibers and skeletal myoblast transplantation in infarcted myocardium. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2008, 87B, 222-228.	1.6	57
20	Protease-Resistant Stromal Cell–Derived Factor-1 for the Treatment of Experimental Peripheral Artery Disease. Circulation, 2011, 123, 1306-1315.	1.6	53
21	Mechanisms of the Multitasking Endothelial Protein NRC-1 as a Compensatory Factor During Chronic Heart Failure. Circulation: Heart Failure, 2019, 12, e006288.	1.6	44
22	Endothelialitis plays a central role in the pathophysiology of severe COVID-19 and its cardiovascular complications. Acta Cardiologica, 2021, 76, 109-124.	0.3	42
23	Engineering insulinâ€like growth factorâ€1 for local delivery. FASEB Journal, 2008, 22, 1886-1893.	0.2	36
24	Pulmonary hypertension and right heart failure in heart failure with preserved left ventricular ejection fraction. Current Opinion in Cardiology, 2012, 27, 273-280.	0.8	36
25	Neuregulin-1 attenuates development of nephropathy in a type 1 diabetes mouse model with high cardiovascular risk. American Journal of Physiology - Endocrinology and Metabolism, 2016, 310, E495-E504.	1.8	32
26	Neuregulin-1 attenuates stress-induced vascular senescence. Cardiovascular Research, 2018, 114, 1041-1051.	1.8	32
27	Autocrine Signaling in Cardiac Remodeling: A Rich Source of Therapeutic Targets. Journal of the American Heart Association, 2021, 10, e019169.	1.6	28
28	The future of pleiotropic therapy in heart failure. Lessons from the benefits of exercise training on endothelial function. European Journal of Heart Failure, 2017, 19, 603-614.	2.9	27
29	The role of endothelial autocrine NRG1/ERBB4 signaling in cardiac remodeling. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 319, H443-H455.	1.5	23
30	The role of endothelial miRNAs in myocardial biology and disease. Journal of Molecular and Cellular Cardiology, 2020, 138, 75-87.	0.9	20
31	Short-Term Angiotensin II Treatment Affects Large Artery Biomechanics and Function in the Absence of Small Artery Alterations in Mice. Frontiers in Physiology, 2018, 9, 582.	1.3	16
32	Endogenous inhibitors of hypertrophy in concentric versus eccentric hypertrophy. European Journal of Heart Failure, 2007, 9, 352-356.	2.9	13
33	ERBB4 and Multiple MicroRNAs That Target ERBB4 Participate in Pregnancy-Related Cardiomyopathy. Circulation: Heart Failure, 2021, 14, e006898.	1.6	12
34	Cardiac endothelial cell transcriptome in neonatal, adult, and remodeling hearts. Physiological Genomics, 2019, 51, 186-196.	1.0	9
35	Epigenetic regulation of intercellular communication in the heart. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H1417-H1425.	1.5	9
36	Neuregulin-1 compensates for endothelial nitric oxide synthase deficiency. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 320, H2416-H2428.	1.5	8

VINCENT F SEGERS

#	Article	IF	CITATIONS
37	Letter Regarding Article by Okoshi et al, "Neuregulins Regulate Cardiac Parasympathetic Activity: Muscarinic Modulation of β-Adrenergic Activity in Myocytes From Mice With Neuregulin-1 Gene Deletion― Circulation, 2005, 111, e175; author reply e175.	1.6	7
38	Pathophysiology of diastolic dysfunction in chronic heart failure. Future Cardiology, 2013, 9, 711-720.	0.5	7
39	Coronaryâ€subclavian steal syndrome, an easily overlooked entity in interventional cardiology. Catheterization and Cardiovascular Interventions, 2020, 96, 614-619.	0.7	5
40	Inhibition of heme oxygenase?1 impairs cardiac muscle sensitivity to beta?adrenergic stimulation. Basic Research in Cardiology, 2005, 100, 224-230.	2.5	4
41	Comparison of radial access versus femoral access with the use of a vascular closure device for the prevention of vascular complications and mortality after percutaneous coronary intervention. Acta Cardiologica, 2018, 73, 241-247.	0.3	4
42	INSPIRE: A European training network to foster research and training in cardiovascular safety pharmacology. Journal of Pharmacological and Toxicological Methods, 2020, 105, 106889.	0.3	4
43	Evidence and Indications for Percutaneous Closure of the Left Atrial Appendage. Revista Espanola De Cardiologia (English Ed), 2018, 71, 700-702.	0.4	3
44	Evidencia e indicaciones del cierre percutáneo de la orejuela izquierda. Revista Espanola De Cardiologia, 2018, 71, 700-702.	0.6	3
45	Combined obesity and psychosocial stress is a worldwide health problem and a paracrine disorder. EBioMedicine, 2019, 48, 13-15.	2.7	3
46	Pathophysiology of Heart Failure: Back to Basics. , 2013, , 3-23.		1
47	Unlike HbA1c level and the amount of visceral adipose tissue, the presence and severity of NAFLD do not predict the occurrence of major adverse cardiovascular events in an obese Belgian population.	1.8	О